Compare Inovio Pharmaceuticals Inc (INO) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs LTC Properties Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while LTC Properties Inc trades at $38.8 (market cap $2.05B). The key difference: LTC Properties Inc is far larger — about 26.1× Inovio Pharmaceuticals Inc's market cap, and LTC Properties Inc pays a 5.98% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LTC | |
|---|---|---|
Market Cap | $78.55M | $2.05B |
Sector | Health | Real Estate |
52-Week High | $2.87 | $42.81 |
52-Week Low | $0.66 | $33.98 |
Enterprise Value | $49.56M | $2.79B |
Dividend Yield | — | 5.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
LTC Properties (LTC) trades at $38.32, down 2.79% over 24 hours, with a bullish technical signal driven by moving averages. The REIT shows strong profitability with a 61.72% gross margin and 38.93% net margin, though recent earnings missed estimates in two of the last three quarters. Recent news highlights aggressive expansion in seniors housing acquisitions, including a $95 million SHOP purchase announced August 5, 2026.
Outlook is mixed: demographic trends support long-term demand, but execution risks from rapid growth and debt-funded investments pose challenges. Analysts are cautious with 59% hold ratings, reflecting concerns over earnings consistency amid high capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
